Navigation Links
Key to treating cancer may be finding its original cell
Date:8/11/2008

e to GNPs went on to form medulloblastoma tumors.

According to Wechsler-Reya, these studies provide the first definitive proof that medulloblastoma can be triggered in a granule neuron precursor or a stem cell. But even more importantly, they suggest that when it comes to cancer formation, the cell type in which a mutation happens is as important as the mutation itself. Although stem cells that lack patched also gave rise to other forms of brain cells, those cells did not form the tumors.

"Simply mutating a gene is not enough to cause cancer," Wechsler-Reya said. "The mutation has to happen in the right cell type at the right time. In the case of patched, GNPs provide the critical context for tumor formation."

Wechsler-Reya said that cancer biologists need to learn more about the genes that regulate proliferation (cell division), differentiation, survival, and programmed cell death in normal cells. A mutation in a proliferation gene, for example, can send the cell on a path of exaggerated division of cells -- becoming a fast-growing tumor. Understanding the way these genes are controlled during normal development can shed light on how they go awry in human cancers.


'/>"/>

Contact: Mary Jane Gore
mary.gore@duke.edu
919-660-1309
Duke University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study provides clues to preventing and treating cancer spread
2. Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments
3. Treating rare breast cancer with radiation therapy may lower recurrence rate
4. UT Southwestern launches study of surgical option for treating diabetic and other neuropathies
5. Louisiana Improves Law for Treating Mentally Ill
6. New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
7. New system devised to guide doctors treating patients with symptomatic myocardial bridging
8. NACDS Praises House Legislation to Delay Medicaid Cuts, Aid Pharmacies in Treating Patients
9. Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
10. HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
11. New Heart Ultrasound Research Shows Hope for Diagnosing and Treating Fatal Heart Conditions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Petersburg, FL (PRWEB) June 19, 2013 ... 5 minutes a day could boost your health and ... Kathy Heshelow, founder of Sublime Beauty®. "It is called ... practiced for centuries but became a lost art. Now, ... celebrities know about Skin Brushing, and so do certain ...
(Date:6/18/2013)... June 19, 2013 An apple a ... Christina Beauregard was diagnosed with breast cancer, she chose ... new book, “I Gave Myself Cancer, I Can Take ... by Balboa Press), Beauregard explains how changing her physical, ... "Sick people have been made to feel fearful when ...
(Date:6/18/2013)... June 18, 2013 Daily Gossip Magazine has ... reviews and useful articles. , The magazine has decided ... to a new anabolic recipe every week . ... is the perfect guide for readers who are looking to ... at Daily Gossip reveals that anabolic food is almost entirely ...
(Date:6/18/2013)... 19, 2013 The Drug Delivery Partnering ... access to the drug delivery partnering deals and agreements ... , The report provides a detailed understanding and analysis ... deals. The majority of deals are discovery or development ... option right to license the license drug delivery technology. ...
(Date:6/18/2013)... Horsham, PA (PRWEB) June 18, 2013 Senior ... in Boston on June 25 to discuss—for the first time ... agencies in getting drugs through the regulatory process in a ... of drug evaluation will share respective best practices and processes ... Across the Strait panel at the DIA 2013 ...
Breaking Medicine News(10 mins):Health News:The Easiest Way to Contribute to Better Health and Well-Being Starting Today and for Under $20, Says Sublime Beauty® 2Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
... Inc. (NYSE:,CVD), a leading provider of drug development ... Merck & Co., Inc.,s Outstanding,Strategic Collaboration Award., ... 12 suppliers who,were selected from thousands of Merck ... performance; contributions towards the Key,Business Result (KBR) for ...
... GXDX ), a specialized laboratory services provider, today reported,revenues ... and $50.1 million,for the first half of 2008, as ... the respective periods in 2007. Stated revenue for the,first ... changes in,accounting estimates relating to prior periods., "Our ...
... mortality 25% in chronic kidney cases , , THURSDAY, July ... -- a routinely measured marker of bone disease -- ... receiving dialysis for chronic kidney disease, say U.S. researchers. ... patients during a three-year period. It found that patients ...
... COMMERCIAL LAUNCH OF HEARTMATE II(R) ... FOR BRIDGE-TO-TRANSPLANTATION, PLEASANTON, Calif., July 31 ... support therapies to save, support and restore failing hearts,today said that ... in the same period a year ago., Revenues for the ...
... she had hearing loss at 30, when she volunteered to ... sounds she could not hear. , Her husband Larry, ... history. Her mother, grandfather and great-grandfather had severe hearing loss ... before he reached school age. , The hearing loss ...
... 31 HealthSouth,Corporation (NYSE: HLS ) ... owned,subsidiaries, its previously announced purchase of The ... rehabilitation hospital in,Vineland, NJ, from The Mediplex/Cumberland ... South Jersey, under the outstanding,leadership of Dr. ...
Cached Medicine News:Health News:Covance Recognized for Outstanding Performance by Merck & Co., Inc. 2Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 2Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 3Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 4Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 5Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 6Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 7Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 8Health News:Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008 9Health News:Bone Disease Test Shows Death Risk for Dialysis Patients 2Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 2Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 3Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 4Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 5Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 6Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 7Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 8Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 9Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 10Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 11Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 12Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 13Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 14Health News:Thoratec Reports 44 Percent Increase in Second Quarter Revenues; 15Health News:Inherited form of hearing loss stems from gene mutation 2Health News:Inherited form of hearing loss stems from gene mutation 3Health News:HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital 2Health News:HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital 3
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 Decision ... for pharmaceutical and healthcare issues, finds that, over the past ... ( France , Germany , ... and the United Kingdom ) have been ... most of their HIV patients, primarily to reduce costs. Additionally, ...
(Date:6/18/2013)... -- Today, Wall Street Reports announced new research ... Health Management Associates Inc. (NYSE: HMA ), IDEXX ... (NASDAQ: ISIS ), and Trius Therapeutics Inc. (NASDAQ: ... - including full price targets, industry analysis and analyst ratings ... Research Report On June 7, 2013, Gilead Sciences ...
(Date:6/18/2013)... , June 18, 2013 Apama Medical, ... the development of next-generation atrial fibrillation technologies, today ... by the US Patent and Trademark Office (USPTO), ... profile electrode assemblies for use on expandable structures ... other surgical procedures. "We are grateful ...
Breaking Medicine Technology:One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 2One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 2Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 3Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 4Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 5Industry Shows a Healthy Pulse with Priority Reviews, Positive Results, New Testing Procedures, and Partnerships - Research Report on Gilead, Health Management, IDEXX, ISIS, and Trius Therapeutics 6
... EVEN MORE SCIENCE SUPPORTING THE, THEORY THAT ... Mo., May 19 A primate model for ... at the,International Meeting For Autism Research (IMFAR) this ... into vaccine safety and,the immune and mitochondrial dysfunction ...
... Native Bladder by Six Months; Data Presented at May 18 Press ... ... ORLANDO, Fla. and EAST NORRITON, Pa., May 19 Tengion,Inc., a ... presented preclinical efficacy data for its,Tengion Neo-Bladder Replacement(TM) at the Annual ...
Cached Medicine Technology:UPDATE: Infant Primates Given Vaccines on U.S. Children's Immunization Schedule Develop Behavioral Symptoms of Autism 2Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM) 2
Iron / TIBC (Ferrozine). Storage temp: 2 - 8 C. Linearity: 0 - 500 ug/dl. Expected values: from TIBC 250 - 400 ug/dl, from Iron 40 - 160 ug/dl. Available with Calibrator and Number of test are 100....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Medicine Products: